Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-066907
Filing Date
2025-05-08
Accepted
2025-05-08 16:05:22
Documents
76
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q eypt-20250331.htm   iXBRL 10-Q 1963919
2 EX-10.1 eypt-ex10_1.htm EX-10.1 66079
3 EX-31.1 eypt-ex31_1.htm EX-31.1 14583
4 EX-31.2 eypt-ex31_2.htm EX-31.2 15052
5 EX-32.1 eypt-ex32_1.htm EX-32.1 6615
6 EX-32.2 eypt-ex32_2.htm EX-32.2 6724
  Complete submission text file 0000950170-25-066907.txt   8799411

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT eypt-20250331.xsd EX-101.SCH 1313453
78 EXTRACTED XBRL INSTANCE DOCUMENT eypt-20250331_htm.xml XML 1601159
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

EIN.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-51122 | Film No.: 25925926
SIC: 3826 Laboratory Analytical Instruments
(CF Office: 08 Industrial Applications and Services)